Mirati Therapeutics company information, Employees & Contact Information

Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer PR Newswire

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor ACS Publications

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO® PR Newswire

Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer PR Newswire

Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies PR Newswire

U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer PR Newswire

Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers PR Newswire

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Ca PR Newswire

Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director PR Newswire

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) PR Newswire

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure PR Newswire

Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates PR Newswire

Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates PR Newswire

Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates PR Newswire

Mirati Therapeutics Announces Pricing of Upsized Public Offering PR Newswire

Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation PR Newswire

Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek PR Newswire

Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire

Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer PR Newswire

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates PR Newswire

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China PR Newswire

Mirati To Present Updated Clinical Data at ESMO Congress 2023 PR Newswire

Synthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug for the Treatment of Cancer ACS Publications

Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein ACS Publications

Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155 PR Newswire

Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team PR Newswire

Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer PR Newswire

Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC) PR Newswire

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire

Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers PR Newswire

Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®) PR Newswire

Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation PR Newswire

Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagras MultiVu

Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors PR Newswire

Synthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug for the Treatment of Cancer ACS Publications

Mirati Therapeutics Announces Executive Management Changes PR Newswire

EX-99.1 SEC.gov

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction ACS Publications

Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire

Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs PR Newswire

Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer PR Newswire

Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors Business Wire

Mirati Therapeutics Announces Proposed Public Offering Of Common Stock PR Newswire

Mirati Therapeutics Provides Progress Update On Current Clinical Trials PR Newswire

Mirati Therapeutics Announces Appointment Of Dr. Bruce L.A. Carter To Board Of Directors PR Newswire

Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition PR Newswire

Zirconium Hydride Catalysis Initiated by Tetrabutylammonium Fluoride ACS Publications

Adagrasib’s Second-Generation Synthesis: Transitioning from Route Scouting to Optimization ACS Publications

Krazati From Mirati Therapeutics Pharmacy Times

Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs PR Newswire

Ben Hickey Bristol Myers Squibb

Scalable Atroposelective Synthesis of MRTX1719: An Inhibitor of the PRMT5/MTA Complex ACS Publications

Journal of Internal Medicine Wiley Online Library

Stereochemical Editing via Coupled Epimerization and Optical Resolution to Sustainably Manufacture a Key Adagrasib Building Block ACS Publications

Bristol Myers Squibb buys Mirati for up to $5.8B as I-O giant branches out into targeted therapy for cancer Fierce Pharma

FDA news: Fast track for glioblastoma drug, breakthrough designation for leukemia therapy Healio

FDA Grants Breakthrough Therapy Designation to Adagrasib, Cetuximab Combination Pharmacy Times

Combining Mirati's KRAS G12D inhibitor with immunotherapy halts pancreatic cancer in mice Fierce Biotech

The Many Shades of KRAS: Investigators Seek to Exploit Heterogeneity in Mutations OncLive